Rocket Pharmaceuticals (RCKT) Announces Proposed Common Share Offering

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announces that it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. Rocket also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. All the shares in the offering are to be sold by Rocket. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Rocket intends to use the net proceeds from the offering to further fund the development of its pipeline of gene therapies for rare diseases, to support the buildout of in-house manufacturing capabilities, and for general corporate purposes.

J.P. Morgan, Cowen and Evercore ISI are acting as the joint-bookrunning managers for the public offering.

You May Also Be Interested In

• Venu Holding enters $250 million at-the-market stock offering agreement
• Atossa Therapeutics closes $4.5 million registered direct offering
• American Homes 4 Rent (AMH) files mixed shelf